Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Jun 26, 2024

BUY
$72.35 - $88.99 $72 - $88
1 New
1 $53,000
Q1 2024

May 13, 2024

BUY
$72.35 - $88.99 $144 - $177
2 New
2 $131,000
Q4 2023

Jun 26, 2024

SELL
$42.42 - $80.28 $84 - $160
-2 Closed
0 $19,000
Q4 2023

Feb 15, 2024

BUY
$42.42 - $80.28 $0 - $0
0 New
0 $0
Q3 2023

Nov 15, 2023

SELL
$39.12 - $49.85 $1,643 - $2,093
-42 Closed
0 $0
Q2 2023

Aug 08, 2023

BUY
$23.58 - $44.68 $990 - $1,876
42 New
42 $44,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.14B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Financial Gravity Asset Management, Inc. Portfolio

Follow Financial Gravity Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.